Dieng, Mbathio
Lord, Sarah J.
Turner, Robin M.
Nieweg, Omgo E.
Menzies, Alexander M.
Saw, Robyn P. M.
Einstein, Andrew J.
Emmett, Louise
Thompson, John F.
Lo, Serigne N.
Morton, Rachael L.
Funding for this research was provided by:
University of Sydney, Robinson Fellowship
Cancer Australia, Priority-driven Collaborative Cancer Research Scheme gran (1129568)
National Health and Medical Research Council (1135285, 1150989)
University of Sydney
Article History
Received: 26 February 2021
Accepted: 2 November 2021
First Online: 10 February 2022
Disclosures
: Robyn P.M. Saw is supported by MIA and has received honoraria for advisory board participation from MSD, Novartis, and Qbiotics, and speaking honoraria from BMS. John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK, and Provectus Inc.; travel support from GSK and Provectus Inc.; and support for conference attendance from Novartis. Alexander M. Menzies reports advisory board fees from BMS, MSD, Novartis, Roche, Pierre-Fabre, and QBiotics. Andrew J. Einstein reports receiving grant funding (paid to Columbia University) for unrelated research, from the National Heart Lung, and Blood Institute, the National Cancer Institute, International Atomic Energy Agency, Canon Medical Systems, GE Healthcare, Roche Diagnostics, and W.L. Gore & Associates; and consulting/lecturing fees from Ionetix and W.L. Gore & Associates. Mbathio Dieng, Sarah J. Lord, Robin Turner, Omgo E. Nieweg, Louise Emmett, Serigne N. Lo, and Rachael L Morton have no conflicts of interest to declare.